<?xml version='1.0' encoding='utf-8'?>
<document id="31203438"><sentence text="Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system." /><sentence text="To investigate the occurrence of myopathy with oral glucose-lowering drugs (OGLDs) and statins, with a focus on dipeptidyl peptidase-4 inhibitors (DPP4-is)"><entity charOffset="52-59" id="DDI-PubMed.31203438.s2.e0" text="glucose" /></sentence><sentence text="" /><sentence text="The FDA adverse event reporting system (FAERS) was queried (2004-2016) to compare the proportion of adverse events with OGLDs, alone and in combination with statins, using the reporting odds ratio (ROR) with relevant 95% confidence interval (95%Cl), adjusted for sex, age and concomitant presence of other OGLDs/lipid-lowering drugs" /><sentence text=" Drug-drug interaction is claimed whenever the frequency of an event is enhanced by combination treatment" /><sentence text=" Consistency/robustness of findings was tested by applying additive/multiplicative models and accounting for competition bias (i" /><sentence text="e" /><sentence text=", adverse events previously known to be associated with OGLDs were removed)" /><sentence text="" /><sentence text="Over a 13-year period, we retrieved 142,888 cases of myopathy" /><sentence text=" The use of DPP4-is alone was not associated with higher reporting of myopathy (no" /><sentence text=" of cases = 4898; adjusted ROR = 1" /><sentence text="00; 95%CI = 0" /><sentence text="96-1" /><sentence text="04), with the notable exclusion of vildagliptin (262; 1"><entity charOffset="35-47" id="DDI-PubMed.31203438.s15.e0" text="vildagliptin" /></sentence><sentence text="64; 1" /><sentence text="42-1" /><sentence text="88)" /><sentence text=" No increased occurrence emerged when used in combination with statins, with consistent findings from additive/multiplicative models for all DPP4-is" /><sentence text=" Likewise, no increased reporting was found for other OGLDs (28,964; 0" /><sentence text="64; 0" /><sentence text="62-0" /><sentence text="67); data on the interaction with statins were consistent/robust across analyses only for sulfonylureas (the interaction is likely and biologically plausible) and sodium glucose cotransporter-2 inhibitors"><entity charOffset="90-103" id="DDI-PubMed.31203438.s23.e0" text="sulfonylureas" /><entity charOffset="163-177" id="DDI-PubMed.31203438.s23.e1" text="sodium glucose" /><pair ddi="false" e1="DDI-PubMed.31203438.s23.e0" e2="DDI-PubMed.31203438.s23.e0" /><pair ddi="false" e1="DDI-PubMed.31203438.s23.e0" e2="DDI-PubMed.31203438.s23.e1" /></sentence><sentence text="" /><sentence text="Real-world FAERS data do not raise concern for muscular toxicity with DPP4-is in combination with statins, making a drug interaction very unlikely" /><sentence text="" /></document>